FDA approves Oyster Point’s nasal spray for dry eye disease

Published by

(Reuters) -Drug developer Oyster Point Pharma Inc said on Monday the U.S. Food and Drug Administration had approved its nasal spray treatment for dry eye disease. The company said the spray, Tyrvaya, will be available from next month to patients with a prescription. The regulator’s decision was based on safety and efficacy results from a late-stage and two mid-stage trials covering over 1,000 patients with mild, moderate or severe symptoms of dry eye disease (DED). More than 30 million people in the United States are affected by the chronic condition characterized by stinging, sensitivity to l…

Read More

Leave a Reply